Our investigations into MEF-2 and HTLV-1 [26–40] are now providing rationale towards potential therapeutic strategies against virally induced ATLL based upon MEF-2: HDAC interactions. The gene discussed is MEF2A; the disease is adult T-cell leukemia/lymphoma.